Many patients focus only on the implant itself, but these supporting procedures are essential for successful outcomes.
Tooth regrowth drug TRG035 is moving towards Phase II trials in patients with severe congenital hypodontia after new funding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results